Sector
Expertise

Life
Sciences

Life Sciences pharmaceuticals, biotechnology, consumer health, diagnostics, digital health, robotics and medical devices

We are skilled at finding senior executives and experts, renowned scientists, clinicians and researchers worldwide, and assessing them from both a leadership and scientific perspective.

Whether you are a start-up, an established corporation, or a CDMO, working on pre-clinical or clinical development, or commercialisation, we’ll help you build collaborative teams. We are skilled in customising our approach to attract diverse, globally-experienced leaders for science-driven environments.

Graphic

Key Trends in Life Sciences

Diversity and Sustainability

Global patient demographics, emerging market demands and opportunities, and an increasingly female talent pool require inclusive leadership. Business leaders must become adept at recognising and prioritising the importance of diversity to harness its advantages for business and society.

When it comes to sustainability, we aspire to the same standards as our clients. We are proud to have been awarded a Bronze rating by Ecovadis in 2022.

1

Collaboration

New business models require collaborative approaches to pipeline innovation, manufacturing and supply, and myriad bench-to-bedside translations. This matrix of layered initiatives requires leaders at all levels of the organisation to be capable of cutting across traditional disciplines through influence, persuasion and compromise.

2

Precision and Personalised Medicine

The scientific advances that are giving rise to precision and personalised medicine are some of the great disruptors of our time. The radical changes that will emerge require leaders to be highly flexible, broad thinkers, who are comfortable challenging and ultimately dismantling the status quo.

3

Value-Driven Patient Access in a Limited Resource Healthcare Ecosystem

Long-term strategic planners who can realistically assess risk and make tough R&D decisions are needed to lead life science companies. They must provide value-driven access to a wide variety of customers and stakeholders in a healthcare ecosystem with limited resources, as well as develop innovative products and therapies. Alternative channels to market will be an inevitable component of any new strategy.

4

Diversity and Sustainability

Global patient demographics, emerging market demands and opportunities, and an increasingly female talent pool require inclusive leadership. Business leaders must become adept at recognising and prioritising the importance of diversity to harness its advantages for business and society.

When it comes to sustainability, we aspire to the same standards as our clients. We are proud to have been awarded a Bronze rating by Ecovadis in 2022.

5

Big Data, Digitalization, and Artificial Intelligence

Big data collection and usage; digitalization; and artificial intelligence in the entire life-cycle of therapies, from development to the point of patient access, are unstoppable trends. Wielding these technology tools in a meaningful way requires innovation leadership that is balanced by well-defined change management skills and a keen ability to prioritise.

Latest News in Life Sciences

February 25, 2024

Pharma CFOs need R&D vigilance in tough economic times

Life sciences

As inflation, high interest rates and a tight investment environment continue to create headaches, 72% of CFOs said economic volatility poses the same or greater risk to their business this year compared to 2023 in a recent survey from BDO — and there are more changes afoot.

February 25, 2024

Agilent CEO Mike McMullen to retire, succeeded by lab services head

Life sciences

McMullen, who’s also currently president of Agilent, is set to abdicate both roles on May 1, according to an announcement the company put out Wednesday afternoon. From there, McMullen will spend a few months serving as an advisor to Agilent and to his successor until his retirement becomes final on Oct. 31.

February 25, 2024

AstraZeneca completes Gracell Biotechnologies acquisition for $1.2bn

Life sciences

AstraZeneca has concluded its acquisition of China-based clinical-stage biopharmaceutical company Gracell Biotechnologies for $1.2bn. The acquisition, initially agreed in December 2023, positions Gracell as a wholly owned AstraZeneca subsidiary with operations continuing in the US and China.

Subscribe to our Weekly Newsletter

Understanding your business is our business

How can we help you?

We're easy to reach